LENZ (LENZ Therapeutics) Other Current Liabilities: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LENZ LENZ Therapeutics Inc LENZ
12 GF Score
Price $4.93
! 2 Warning Signs
View Full Analysis

What is LENZ Therapeutics Other Current Liabilities?

LENZ Therapeutics LENZ -5.74% 12 Other Current Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates LENZ with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

LENZ Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.


LENZ Therapeutics Other Current Liabilities Related Terms


LENZ Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for LENZ Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LENZ Therapeutics Other Current Liabilities Chart

LENZ Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
0.00 0.00 0.00 0.00 0.00

LENZ Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LENZ
12GF Score
LENZ Therapeutics Inc LENZ
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LENZ Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.00 Mil mean?
LENZ Therapeutics (LENZ) has a Other Current Liabilities of $0.00 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on LENZ Therapeutics.
Is LENZ Therapeutics' Other Current Liabilities too high?
LENZ Therapeutics' current Other Current Liabilities is $0.00 Mil. Overall, LENZ Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LENZ Therapeutics' Other Current Liabilities compare to KRRO and ANTX?
LENZ Therapeutics' Other Current Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on LENZ Therapeutics. LENZ Therapeutics's current Other Current Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LENZ Therapeutics stock overvalued right now?
LENZ Therapeutics (LENZ) has a current Other Current Liabilities of $0.00 Mil. The current Other Current Liabilities is $0.00 Mil. LENZ Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For LENZ Therapeutics (LENZ), the current Other Current Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LENZ Therapeutics Business Description

Address 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA, USA, 92075
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
12GF Score

Get the complete analysis for LENZ

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.93
Price